Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
CURRENC Group | CURR | Nov 22, 2024 | 1.81 | 0.00 |
Curtiss-Wright | CW | Nov 22, 2024 | 370.82 | +0.89 |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Nov 22, 2024 | 44.39 | -0.80 |
Cushman & Wakefield | CWK | Nov 22, 2024 | 14.44 | +2.12 |
Custom Truck One Source | CTOS | Nov 22, 2024 | 5.72 | +8.95 |
Customers Bancorp | CUBI | Nov 22, 2024 | 56.11 | +1.50 |
Customers Bancorp E Pref | CUBI-E | Nov 22, 2024 | 26.25 | +0.48 |
Customers Bancorp F Pref | CUBI-F | Nov 22, 2024 | 25.73 | -0.27 |
Cutera | CUTR | Nov 22, 2024 | 0.32 | +0.19 |
CVB Financial | CVBF | Nov 22, 2024 | 23.83 | +2.76 |
CVD Equipment | CVV | Nov 22, 2024 | 3.09 | -0.32 |
CVR Energy | CVI | Nov 22, 2024 | 18.74 | 0.00 |
Cvr Partners LP Unit | UAN | Nov 22, 2024 | 71.81 | +0.27 |
CVRx | CVRX | Nov 22, 2024 | 14.85 | +0.54 |
CVS Health | CVS | Nov 22, 2024 | 58.01 | +1.59 |
CXApp A | CXAI | Nov 22, 2024 | 1.41 | +4.44 |
CyberArk Software | CYBR | Nov 22, 2024 | 319.73 | -2.86 |
Cybin | CYBN | Nov 22, 2024 | 9.82 | -3.35 |
Cyclacel Pharmaceuticals | CYCC | Nov 22, 2024 | 0.36 | +2.51 |
Cyclacel Pharmaceuticals Pref | CYCCP | Nov 22, 2024 | 6.94 | 0.00 |
Cyclerion Therapeutics | CYCN | Nov 22, 2024 | 1.43 | +0.70 |
Cyclo Therapeutics | CYTH | Nov 22, 2024 | 0.73 | +4.43 |
Cyngn | CYN | Nov 22, 2024 | 6.10 | -6.59 |
Cytek Biosciences | CTKB | Nov 22, 2024 | 6.55 | +1.39 |
Cytokinetics | CYTK | Nov 22, 2024 | 49.10 | +3.00 |
Cytomed Therapeutics | GDTC | Nov 22, 2024 | 2.26 | +2.70 |
CytomX Therapeutics | CTMX | Nov 22, 2024 | 0.89 | +2.71 |
Cytosorbents | CTSO | Nov 22, 2024 | 0.92 | +3.37 |
D-MARKET Electronic Services & Trading ADR | HEPS | Nov 22, 2024 | 2.81 | +0.72 |
D-Wave Quantum | QBTS | Nov 22, 2024 | 2.93 | +48.73 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.